Antibody-drug conjugates show distinct safety profiles and improve quality of life in metastatic breast cancer.
The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...
As OS Therapies prepares to take its bacteria-based lung cancer therapy to the FDA for approval, the biotech has been ...
Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well ...
Stocktwits on MSN4h
Summit Therapeutics’ Retail Chatter Explodes As Pfizer Trial Pact Drowns Out Q4 LetdownSummit Therapeutics, Inc. shares rebounded in after-hours trading on Monday after a 14% selloff during regular hours, with ...
GlobalData on MSN14h
Pfizer sets sights on Summit’s bispecific in combo with its ADCsSummit’s PD-1 bispecific antibody outperformed MSD’s Keytruda in a Phase III trial enrolling patients with lung cancer.
Under the terms of the Exclusive License, Radiance will pay CSPC an upfront payment of $15 million, and up to $150 million in potential development and regulatory milestone payments and over $1 ...
Corbus Pharmaceuticals presented new data from the first Western study of its antibody-drug conjugate treatment for cancer.
Summit Therapeutics (SMMT) announced a clinical trial collaboration with Pfizer (PFE) to evaluate ivonescimab, an investigational PD-1 / VEGF ...
The company, now based in North Beach, has lost more than $2 billion over 29 years. Its only approved drug, called roxadustat ...
The Hartford Healthcare Fund (I share) underperformed the S&P Composite 1500 Health Care Index during the quarter. Read more ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback